文献速递心力衰竭与心肌病

机器学习多中心风险模型预测机械循环支持后右心衰竭:STOP-RVF评分

Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该多中心混合前瞻-回顾性队列研究基于798例推导队列和327例外部验证队列,开发并验证了预测左心室辅助装置(LVAD)植入后右心衰竭(RVF)的STOP-RVF计算器。模型纳入非缺血性心肌病、IABP、临时MCS、LVAD配置、INTERMACS 1-2级、右房压/肺毛细血管楔压比值、ACEI使用及血小板、钠、白蛋白、肌酐等术前变量,推导队列C统计量0.75,验证队列0.73,优于Kormos等(0.58)和Drakos等(0.62)的评分。

要点

  • STOP-RVF计算器仅用常规临床数据即可个体化预测LVAD术后RVF风险。
  • 推导队列RVF发生率24.2%,外部验证队列32.7%。
  • 模型区分度C统计量推导0.75、验证0.73,优于既往常用评分。

核心结论

  • STOP-RVF计算器可作为LVAD候选者RVF及RVF相关全因死亡的个体化风险评估工具。

研究设计与样本

  • 多中心混合前瞻-回顾性队列研究,2008年4月至2019年7月纳入晚期心衰需持续流LVAD患者。
  • 推导队列来自5家机构共798例,外部验证队列来自第6家机构共327例。

主要发现

  • 推导队列RVF发生193/798例(24.2%),验证队列107/327例(32.7%)。
  • 与术后RVF相关的术前变量包括非缺血性心肌病、IABP、微轴经皮LVAD/VA-ECMO、LVAD配置、INTERMACS 1-2级、右房压/肺毛细血管楔压比值、ACEI使用及血小板、钠、白蛋白、肌酐水平。
  • 纳入术中特征未改善模型性能。
  • 计算器C统计量推导队列0.75(95%CI 0.71-0.79),验证队列0.73(95%CI 0.67-0.80)。
  • 低风险组(估计RVF风险<20%)累积生存率高于较高风险组。

关键数值与推荐

  • STOP-RVF计算器C统计量0.75(95%CI 0.71-0.79)优于Kormos等评分0.58(95%CI 0.53-0.63)。
  • STOP-RVF计算器C统计量0.73(95%CI 0.67-0.80)优于Drakos等评分0.62(95%CI 0.57-0.67)。
  • RVF定义为需要右心室辅助装置或静脉正性肌力药物超过14天。

临床怎么用

  • 对拟植入持续流LVAD的晚期心衰患者,可用STOP-RVF计算器术前评估RVF风险。
  • 低风险(估计RVF风险<20%)患者术后累积生存率更高,可辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support might be limited, partly due to lack of external validation, marginal predictive power, and absence of intraoperative characteristics. OBJECTIVE: To derive and validate a risk model to predict RVF after LVAD implantation. DESIGN, SETTING, AND PARTICIPANTS: This was a hybrid prospective-retrospective multicenter cohort study conducted from April 2008 to July 2019 of patients with advanced heart failure (HF) requiring continuous-flow LVAD. The derivation cohort included patients enrolled at 5 institutions. The external validation cohort included patients enrolled at a sixth institution within the same period. Study data were analyzed October 2022 to August 2023. EXPOSURES: Study participants underwent chronic continuous-flow LVAD support. MAIN OUTCOME AND MEASURES: The primary outcome was RVF incidence, defined as the need for RV assist device or intravenous inotropes for greater than 14 days. Bootstrap imputation and adaptive least absolute shrinkage and selection operator variable selection techniques were used to derive a predictive model. An RVF risk calculator (STOP-RVF) was then developed and subsequently externally validated, which can provide personalized quantification of the risk for LVAD candidates. Its predictive accuracy was compared with previously published RVF scores. RESULTS: The derivation cohort included 798 patients (mean [SE] age, 56.1 [13.2] years; 668 male [83.7%]). The external validation cohort included 327 patients. RVF developed in 193 of 798 patients (24.2%) in the derivation cohort and 107 of 327 patients (32.7%) in the validation cohort. Preimplant variables associated with postoperative RVF included nonischemic cardiomyopathy, intra-aortic balloon pump, microaxial percutaneous left ventricular assist device/venoarterial extracorporeal membrane oxygenation, LVAD configuration, Interagency Registry for Mechanically Assisted Circulatory Support profiles 1 to 2, right atrial/pulmonary capillary wedge pressure ratio, use of angiotensin-converting enzyme inhibitors, platelet count, and serum sodium, albumin, and creatinine levels. Inclusion of intraoperative characteristics did not improve model performance. The calculator achieved a C statistic of 0.75 (95% CI, 0.71-0.79) in the derivation cohort and 0.73 (95% CI, 0.67-0.80) in the validation cohort. Cumulative survival was higher in patients composing the low-risk group (estimated <20% RVF risk) compared with those in the higher-risk groups. The STOP-RVF risk calculator exhibited a significantly better performance than commonly used risk scores proposed by Kormos et al (C statistic, 0.58; 95% CI, 0.53-0.63) and Drakos et al (C statistic, 0.62; 95% CI, 0.57-0.67). CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Taleb I, Kyriakopoulos CP, Fong R, et al. Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score. JAMA Cardiol. 2024. PMID: 38294795. doi:10.1001/jamacardio.2023.5372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。